Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 3000 participants.
Also called NCT06492291
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,000 participants
- Sponsor
- Registry
-
NCT06492291 -
2023-504922-20-00 -
U1111-1290-3950 -
jRCT2051240110
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Singapore, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06492291. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-05 (actual); primary completion 2028-10-13 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Enlicitide Decanoate
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct06492291- Content hash
ccb4e205b3f771780c6400bbf4b074b122d84e54d031feea31d9f61bebb7f8e6